TMCnet News
Meta-Analysis Provides Wide-Ranging Proof EndoGastric Solutions' Transoral Incisionless Fundoplication (TIF®) Procedure Successfully Treats GERDEndoGastric Solutions® (EGS), a leader in incisionless procedural therapy for gastroesophageal reflux disease (GERD), announced today the results of a meta-analysis demonstrating that EGS' Transoral Incisionless Fundoplication (TIF®) procedure with the EsophyX® device significantly improves patients' quality of life (HRQL), while reducing their reliance on proton pump inhibitor (PPI) drugs. The meta-analysis is being presented as a poster (SU1137), today 9:30 AM - 4:00 PM at the Digestive Disease Week (DDW) annual meeting in San Diego, California. According to the meta-analysis, "Efficacy of Transoral Incisionless Fundoplication for Gastroesophageal Reflux Disease":
"Our research further validates the significant benefits of transoral incisionless fundoplication, demonstrating that the procedure has, since its introduction, effectively treated the underlying cause of GERD while ending patients' reliance on PPI," said Lauren B. Gerson, MD, MSC (News - Alert), gastroenterologist at California Pacific Medical Center in San Francisco. Dr. Gerson presented the meta-analysis in a poster session at DDW, along with Karim S. Trad, MD, Clinical Professor of Surgery with The George Washington University School of Medicine & Health Sciences. For the meta-analysis, Drs. Gerson and Trad used research databases PubMed, Embase, and SCOPUS to examine data from three RCTs and seven cohort studies from the past eight years that examined the TIF procedure and outcomes at least six months after the procedure. "This meta-analysis provides solid clinical evidence that TIF procedure with the EsophyX device is an excellent choice in bringing relief to GERD patients, providing an incisionless, effective alternative to potentially damaging PPI treatment," said Skip Baldino, President and CEO of EndoGastric Solutions. "We thank Dr. Gerson and Dr. Trad for their meticulous research and for their valued contribution to the field of GERD treatment." About DDW Digestive Disease Week® (DDW) is the largest international gathering of physicians, researchers and academics in the fields of gastroenterology, hepatology, endoscopy and gastrointestinal surgery. Jointly sponsored by the American Association for the Study of Liver Diseases (AASLD), the American Gastroenterological Association (AGA) Institute, the American Society for Gastrointestinal Endoscopy (ASGE) and the Society for Surgery of the Alimentary Tract (SSAT), DDW takes place May 21-24, 2016, at the San Diego Convention Center, San Diego, CA (News - Alert). The meeting showcases morethan 5,000 abstracts and hundreds of lectures on the latest advances in GI research, medicine and technology. More information can be found at www.ddw.org. About Transoral Incisionless Fundoplication (TIF®) procedure for reflux Performed without the need for external incisions through the skin, the TIF procedure offers patients who require an anatomical repair another treatment option to correct the underlying cause of GERD. Studies show that for up to three years after the TIF procedure esophageal inflammation (esophagitis) is eliminated and most patients are able to stop using daily PPI medications to control symptoms. Over 17,000 TIF patients have been treated worldwide since EsophyX® device clearance in 2007. More than 60 peer-review papers from over 50 centers have been published documenting consistent outcomes on over 1,100 unique study patients. For more information, visit www.GERDHelp.com. About EsophyX® technology The original EsophyX device was cleared by the FDA in 2007. EGS launched the third generation EsophyX device, the EsophyX Z, in 2015. The technology has continued to evolve and is a clinically backed tool for physician use in the treatment of GERD. The EsophyX technology now enables surgeons and gastroenterologists to use a wider selection of endoscopes - including low profile and larger high-definition models - to treat the underlying anatomical cause of GERD. The EsophyX technology is used to reconstruct the gastroesophageal valve (GEV) and restore its function as a barrier, preventing stomach acids refluxing back into the esophagus. The device is inserted through the patient's mouth with direct visual guidance from an endoscope. About Current Procedural Terminology (CPT®) CPT codes are a listing of descriptive terms and identifying codes for reporting medical services and procedures. The purpose of CPT is to provide a uniform language that accurately describes medical, surgical, and diagnostic services, and thereby serves as an effective means for reliable nationwide communication among physicians and other healthcare providers, patients, and third parties. CPT® is a registered trademark of the American Medical Association. The Federal Register has posted coding and payment information specific to the new CPT code, allowing patients to more easily receive access to treatment for GERD. Physicians and hospitals can reference CPT Code 43210 EGD esophagogastric fundoplasty and APC (News - Alert) 5331 Complex GI Procedures for TIF procedures as of January 1, 2016. In 2015, four primary GI societies - SAGES, AGA, ACG, ASGE - jointly sponsored an application to the American Medical Association for a new Category I Current Procedural Terminology (CPT®) code. CPT 43210: EGD esophagogastric fundoplasty. About GERD Gastroesophageal reflux disease (GERD) is a chronic condition in which the gastroesophageal valve (GEV) allows gastric contents to reflux (wash backwards) into the esophagus, causing heartburn and possible injury to the esophageal lining. The stomach produces hydrochloric acid and other digestive enzymes after a meal to aid in the digestion of food. The cells that line the stomach are coated with a protective mucus that can withstand gastric contents, while the cells that line the esophagus lack the same protection. GERD is the most common gastrointestinal-related diagnosis made by physicians during clinical visits in the U.S. It is estimated that pain and discomfort from acid reflux impacts over 80 million people at least once per month in the U.S. The standard recommendations for symptomatic GERD patients include lifestyle changes (e.g., diet, scheduled eating times, and sleeping positions) and escalating doses of prescription medications for prolonged periods of time. Long-term, maximum-dose usage of prescription medications has been linked to a variety of other health complications. About EndoGastric Solutions® Based in Redmond, WA, EndoGastric Solutions, Inc. (www.endogastricsolutions.com), is a medical device company focused on developing and commercializing innovative, evidence-based, incisionless surgical technology for the treatment of gastroesophageal reflux disease (GERD). EGS has combined the most advanced concepts in gastroenterology and surgery to develop the Transoral Incisionless Fundoplication (TIF®) procedure - a minimally invasive solution that addresses a significant unmet clinical need. Indications: The EsophyX device with SerosaFuse fasteners is indicated for use in transoral tissue approximation, full thickness plication and ligation in the GI tract and is indicated for the treatment of symptomatic chronic gastroesophageal reflux disease in patients who require and respond to pharmacological therapy. It is also indicated to narrow the gastroesophageal junction and reduce hiatal hernia = 2cm in size in patients with symptomatic chronic gastroesophageal reflux disease. Reference: 1Gerson L, Trad K, Lobontiu A. Efficacy of Transoral Incisionless Fundoplication for Gastroesophageal Reflux Disease: A Meta-Analysis. AGA Institute presentation, DDW. 2016.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160522005033/en/ |
